All In Biotech

Drug Trial Radar · NCT04951622

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 199 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

199

Planned (sponsor's estimate)

Start

Jul 15, 2021

Primary completion

Nov 17, 2023

Study completion Mar 29, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jul 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the subcutaneous substudy is to evaluate how well it works in the body (pharmacodynamic \[PD\]) when given as an injection under the skin (subcutaneous) compared to when given through a vein (intravenous) in participants with gMG.

Conditions

  • Myasthenia Gravis

Interventions

  • NipocalimabDrug

    Nipocalimab will be administered as an IV infusion.

  • PlaceboDrug

    Matching placebo will be administered as an IV infusion.

  • Nipocalimab SC-LIVDrug

    Nipocalimab will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double-blind (DB) Phase: Average Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24Time frame: Baseline, Weeks 22, 23, and 24
  2. Sub Study: Percent Change in Anti-AChR Autoantibody Titer From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)Time frame: From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)
  3. Sub Study: Percent Change in Total IgG Levels From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)Time frame: From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)

Locations

112 sites in 17 countries. Site status is shown where the registry gives one.

  • Neuromuscular Research Center and Clinic

    Paradise Valley, Arizona · Recruiting

  • HonorHealth Neurology

    Scottsdale, Arizona · Completed

  • University of Southern California

    Los Angeles, California · Completed

  • Stanford University

    Palo Alto, California · Completed

  • Care Access Research

    Pasadena, California · Recruiting

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Yale New Haven Hospital

    New Haven, Connecticut · Recruiting

  • FM Clinical Research, LLC South Florida Neurology Associates, P. A.

    Boca Raton, Florida · Recruiting

  • University of Florida Health Jacksonville

    Jacksonville, Florida · Completed

  • Medsol Clinical Research Center Inc

    Port Charlotte, Florida · Recruiting

  • University of South Florida

    Tampa, Florida · Recruiting

  • Augusta University

    Augusta, Georgia · Completed

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • St. Elizabeth Medical Center

    Boston, Massachusetts · Completed

  • Lahey Hospital & Medical Center

    Burlington, Massachusetts · Completed

  • Washington University School Of Medicine

    St Louis, Missouri · Completed

  • Duke University School of Medicine

    Durham, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Completed

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • The Ohio State University

    Columbus, Ohio · Completed

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Wesley Neurology

    Cordova, Tennessee · Completed

  • UT Southwestern Medical Center

    Dallas, Texas · Completed

  • University of Vermont

    Burlington, Vermont · Completed

  • Melbourne Neurology Group

    North Melbourne, Australia · Completed

  • Gold Coast University Hospital

    Southport, Australia · Recruiting

  • ULB Hôpital Erasme

    Anderlecht, Belgium · Recruiting

  • AZ Sint Jan Brugge Oostende AV

    Bruges, Belgium · Recruiting

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium · Recruiting

  • AZ Sint-Lucas

    Ghent, Belgium · Recruiting

  • University Hospitals Leuven

    Leuven, Belgium · Recruiting

  • The Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada · Recruiting

  • Toronto General Hospital

    Toronto, Ontario, Canada · Recruiting

  • McGill University

    Montreal, Quebec, Canada · Completed

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Xuanwu Hospital ,Capital Medical University

    Beijing, China · Completed

  • Beijing Hospital

    Beijing, China · Recruiting

  • The First Bethune Hospital of Jilin University

    Changchun, China · Recruiting

  • Xiangya Hospital Central South University

    Changsha, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, China · Completed

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.